The Merck Serono arm of Merck KGaA is paying an undisclosed up-front payment and could hand over as much as €170 million (US$228 million) more in development and commercial milestones for ex-China rights to Beigene Co. Ltd.’s preclinical poly ADP-ribose polymerase (PARP) inhibitor, Beigene-290.